PROgnostic Signature in stage II colon cancer (CC) patients enrolled in the phase III clinical trial TOSCA: PROSIT study

被引：0
|
作者：
Puccini, A. [1 ,2 ]
Ferrando, L. [3 ]
Mazzarella, L. [4 ]
Frige, G. [5 ]
Pessino, A. [6 ]
Pastorino, A. [7 ]
Martelli, V. [8 ]
Garuti, A. [2 ]
Ballestrero, A. [2 ]
Torri, V. [9 ]
Labianca, R. [10 ]
Fassan, M. [11 ]
Lonardi, S. [12 ]
Zoppoli, G. [13 ,14 ]
Sobrero, A. [15 ]
机构：
[1] IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Rozzano, Italy
[2] IRCCS Humanitas Res Hosp, Med Oncol & Hematol Unit, Rozzano, Italy
[3] IRCCS Osped Policlin San Martino, Dept Internal Med, Genoa, Italy
[4] IEO Ist Europeo Oncol IRCCS, New Drug Dev, Expt Oncol, Milan, Italy
[5] IEO Ist Europeo Oncol, Expt Oncol, Milan, Italy
[6] IRCCS Osped Policlin San Martino, Hematooncol Dept, Genoa, Italy
[7] IRCCS Osped Policlin San Martino, Dept Med Oncol, Genoa, Italy
[8] IRCCS Osped Policlin San Martino, Dipartimento Oncol Med 1, Genoa, Italy
[9] Ist Ric Farmacol Mario Negri IRCCS, Milan, Italy
[10] ASST Papa Giovanni XXIII, Prov Dept Oncol, Bergamo, Italy
[11] Azienda Univ Osped Padova, Padua, Italy
[12] IOV Ist Oncol Veneto IRCCS, Dept Oncol, Padua, Italy
[13] Univ Genoa, Dept Internal Med, Genoa, Italy
[14] Osped Policlin San Martino IRCCS DiMI, Genoa, Italy
[15] IRCCS Osped Policlin San Martino, Dept Med Oncol, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
25P
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [41] Prognostic Subgroups among Patients with Stage II Colon Cancer
    Boland, C. Richard
    Goel, Ajay
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (03): : 277 - 278
  • [42] Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
    I Mochizuki
    H Takiuchi
    K Ikejiri
    Y Nakamoto
    Y Kinugasa
    A Takagane
    T Endo
    H Shinozaki
    Y Takii
    Y Takahashi
    H Mochizuki
    K Kotake
    S Kameoka
    K Takahashi
    T Watanabe
    M Watanabe
    N Boku
    N Tomita
    Y Matsubara
    K Sugihara
    British Journal of Cancer, 2012, 106 : 1268 - 1273
  • [43] Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial
    Mochizuki, I.
    Takiuchi, H.
    Ikejiri, K.
    Nakamoto, Y.
    Kinugasa, Y.
    Takagane, A.
    Endo, T.
    Shinozaki, H.
    Takii, Y.
    Takahashi, Y.
    Mochizuki, H.
    Kotake, K.
    Kameoka, S.
    Takahashi, K.
    Watanabe, T.
    Watanabe, M.
    Boku, N.
    Tomita, N.
    Matsubara, Y.
    Sugihara, K.
    BRITISH JOURNAL OF CANCER, 2012, 106 (07) : 1268 - 1273
  • [44] PHASE-II TRIAL OF CC-49 IN REFRACTORY COLON CANCER
    PODOLOFF, DA
    KASI, LP
    MACEY, DM
    BHADKAMKAR, VA
    RIEGER, P
    CUNNINGHAM, J
    SOUTH, M
    ZHANG, HZ
    ROSENBLUM, MG
    SCHLOM, J
    MURRAY, JL
    JOURNAL OF NUCLEAR MEDICINE, 1993, 34 (05) : P53 - P53
  • [45] Phase II clinical trial of adjuvant chemotherapy with mFOLFOX6/XELOX for stage III colon cancer in Japanese subjects
    Yamada, T.
    Koda, K.
    Ishibashi, K.
    Kato, H.
    Nishimura, G.
    Ooki, S.
    Yoshimatsu, K.
    Uchida, E.
    Kan, H.
    Kosugi, C.
    Tanaka, S.
    Kato, R.
    Kouketsu, S.
    Nakajima, H.
    Maekawa, H.
    Kobayashi, M.
    Tsubaki, M.
    Yokoyama, M.
    Tanakaya, K.
    Ishida, H.
    ANNALS OF ONCOLOGY, 2015, 26 : 55 - 55
  • [46] Clinical impact of mucinous and poorly differentiated tumours on the outcome of patients with stage II colon cancer: A TOSCA subgroup analysis
    Rosati, G.
    Galli, F.
    Cantore, M.
    Lonardi, S.
    Banzi, M.
    Zampino, M. G.
    Mattioli, R.
    Pella, N.
    Ronzoni, M.
    Di Bartolomeo, M.
    Tamberi, S.
    Marchetti, P.
    Bozzarelli, S.
    Corsi, D. C.
    Bochicchio, A. M.
    Artioli, F.
    Labianca, R.
    Galli, F.
    Bilancia, D.
    Bregni, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [47] Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer
    Ishiguro, Megumi
    Mochizuki, Hidetaka
    Tomita, Naohiro
    Shimada, Yasuhiro
    Takahashi, Keiichi
    Kotake, Kenjiro
    Watanabe, Masahiko
    Kanemitsu, Yukihide
    Ueno, Hideki
    Ishikawa, Toshiaki
    Uetake, Hiroyuki
    Matsui, Shigeyuki
    Teramukai, Satoshi
    Sugihara, Kenichi
    BMC CANCER, 2012, 12
  • [48] Study protocol of the SACURA trial: a randomized phase III trial of efficacy and safety of UFT as adjuvant chemotherapy for stage II colon cancer
    Megumi Ishiguro
    Hidetaka Mochizuki
    Naohiro Tomita
    Yasuhiro Shimada
    Keiichi Takahashi
    Kenjiro Kotake
    Masahiko Watanabe
    Yukihide Kanemitsu
    Hideki Ueno
    Toshiaki Ishikawa
    Hiroyuki Uetake
    Shigeyuki Matsui
    Satoshi Teramukai
    Kenichi Sugihara
    BMC Cancer, 12
  • [49] Development and Validation of a Prognostic Nine Gene Expression Signature for Stage II/III Colorectal Cancer Patients
    Cheng, Liang
    Wang, Lisha
    Shen, Xiaohan
    Ren, Fei
    Sheng, Weiqi
    Zhou, Xiaoyan
    Du, Xiang
    LABORATORY INVESTIGATION, 2016, 96 : 165A - 165A
  • [50] Development and Validation of a Prognostic Nine Gene Expression Signature for Stage II/III Colorectal Cancer Patients
    Cheng, Liang
    Wang, Lisha
    Shen, Xiaohan
    Ren, Fei
    Sheng, Weiqi
    Zhou, Xiaoyan
    Du, Xiang
    MODERN PATHOLOGY, 2016, 29 : 165A - 165A
12345